Tropifexor

DB16343InvestigationalSmall molecule

Tropifexor is under investigation in clinical trial NCT02516605 (A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients).

Mechanism: Pharmacologically active on Bile acid receptor
Curator reviewed
Formula / weight: C₂₉H₂₅F₄N₃O₅S · 603.59 g/mol (avg)
Code names: LJN-452 · NVP-LJN452-NXA

Resolves to

Compound

UNIINMZ08KM76ZCAS1383816-29-2ChEMBLCHEMBL4298169

Structure

InChIKeyVYLOOGHLKSNNEK-PIIMJCKOSA-NSMILESOC(=O)C1=CC(F)=C2N=C(SC2=C1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCC1=C(ON=C1C1=C(OC(F)(F)F)C=CC=C1)C1CC1

Targets

Q96RI1NR1H4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tropifexor, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account